As written previously, there is currently no FDA approved treatment that can reverse, arrest or even slow the damage and destruction of brain cells and their connections that is caused by Alzheimer’s disease. While there are drugs approved by the FDA to treat Alzheimer’s disease, these drugs can only provide limited and relatively short-lived symptomatic relief of impaired thinking and memory. They have no effect on the underlying disease progression.
Clearly, new and more effective ways to treat this devastating disease are sorely needed. Research aimed at attempting to better understand and characterize the biological events leading up to this disease, as well as what occurs as the disease progresses both behaviorally and within the brain are areas of intense investigation. With a better understanding of these events, it should be possible to develop targeted approaches to the treatment of this disease. Unfortunately, the development and subsequent approval of drugs is a long and arduous process that leaves those currently battling the disease with only limited options.
To this end, an internet search of memory loss research NYC reveals a significant number of clinical trials currently being conducted throughout the New York City Metropolitan Area focusing specifically on the evaluation of new drugs or drug combinations that may be able to provide better, more effective treatments for the memory loss associated with Alzheimer’s disease. This may be something worth considering as such trials offer the unique opportunity of being able to try a new/experimental drug or drug combination that is not available to the general public and that may ultimately prove to be more effective and/or safer than those currently in use.
If you or someone you know has or suspects that they have memory loss due to Alzheimer’s disease, it is important to do whatever is possible to maintain cognitive and behavioral functioning and independence for as long as possible. Waiting will only make it that much more difficult to realize any significant and protracted clinical benefit.